CarboHyde announces the development of a new pipeline asset in an undisclosed partnership: we will work on the optimization, scale-up, and industrialization of a novel, carbohydrate-based non-viral gene delivery system which provided promising results in proof-of-concept preclinical studies. We expect the technology to be widely compatible with different oligonucleotides and become a safer alternative to currently used LNPs.
The cyclodextrin event of the year is around the corner with world-class speakers from all around the globe delivering talks on all kinds of topics related to our favorite sugars.
Tamas Sohajda from our advisory board talks about cyclodextrins as antiviral agents and drug delivery systems.
We hope to see many new faces there too!
Check out the schedule here: https://www.ismn.cnr.it/ics20/pdf/ICS_program_rev.2022_5_7.pdf
We are happy to announce an expansion of the CarboHyde family. We have invited several world-renowned scientists and experts from different countries and institutions to our Scientific Advisory Board, who can help us in our challenging journey of developing carbohydrate-based therapeutic nutrition agents. We will introduce them one by one in the coming weeks.
Tamas Sohajda has a long professional history in the field of cyclodextrins – he was the head of R&D and CEO of CycloLab for 5+ years – widely experienced in chemistry, analysis, formulation, etc., regulatory affairs, industrialization, and therapeutic applications. We are honored that he accepted our invitation to support us through our upcoming preclinical and clinical development obstacles, feed us new ideas and improve existing ones.
Welcome on board, Tamas!
To better understand the place and the goals of CarboHyde, a private preclinical pharma startup from the EU, a short interview was performed with József Tóth Ph.D., Founder, and CEO of CarboHyde.
Read the full interview below in pdf form
Cyclo Therapeutics, Inc. goes for Phase 2b Study of Trappsol® Cyclo™ for treating early Alzheimer’s disease.
See full post…
A new study shows CLN3, a lysosomal transmembrane protein, is required for the lysosomal clearance of glycerophospholipid and that glycerophosphoinositol is a disease biomarker for Batten disease. Great work to advance lysosomal storage disorder treatments from a team from Stanford University, The National Institutes of Health, Leibniz Institute on Aging – Fritz Lipmann Institute (FLI), Ludwig-Maximilians-Universität München, Whitehead Institute for Biomedical Research, University of Virginia School of Medicine and David Sabatini!
Full article on nature.com
What a great day when we can celebrate Carolyn Bertozzi, a pioneer in glycochemistry, and the fathers of click reaction Barry Sharpless and Morten Meldal, whose innovation we use day-by-day in our humble research.
Thank you for your groundbreaking work that enables many and more new discoveries!
Funding of translational research, using blockchain, NFTs, and a decentralized ownership and decision-making platform? One thing is for sure, it is not a sci-fi anymore.
We are happy to report on the acceptance of Tamas Sohajda‘s new patent on the use of single isomer chemically modified cyclodextrin for treating lysosomal storage diseases. Sugammadex and similar compounds are mentioned as potential active ingredients in this patent.
Our group has always been fond of photodynamic therapy, and here is a great example of why: β-galactosidase activated PDT for selective imaging and targeted treatment of glioblastoma delivered by Orta Doğu Teknik Üniversitesi / Middle East Technical University and Koç University Gorkem Gunbas Toghrul Almammadov Safacan Kölemen
Full article: https://pubs.acs.org/doi/10.1021/acsabm.2c00484